EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSOKIG00005045869
Gene Symbol: KCNK2
3 Cross references
203 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSOKIG00005030913
Gene Symbol: KCNK9
1 Cross references
212 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSOKIG00005045469
Gene Symbol: KCNA5
3 Cross references
168 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSOKIG00005043557
Gene Symbol: KCNA5
3 Cross references
168 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSOKIG00005000914
Gene Symbol: KCND3
3 Cross references
186 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSOKIG00005015538
Gene Symbol: LOC109869514
3 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSOKIG00005009925
Gene Symbol: KCND3
3 Cross references
186 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSOKIG00005036113
Gene Symbol: KCNH2
1 Cross references
180 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSOKIG00005034859
Gene Symbol: KCNH2
3 Cross references
181 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 6

Ensembl ID : ENSOKIG00005038184
Gene Symbol: LOC109874708
3 Cross references
151 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 5

Ensembl ID : ENSOKIG00005041803
Gene Symbol: LOC109899711
2 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSOKIG00005001577
Gene Symbol: KCNQ2
1 Cross references
180 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).